MSD V-PLEX · pg/mL Sensitivity

MSD Aβ40/Aβ42 Assay Service

Quantify amyloid-beta 1–40 and 1–42 peptides in cerebrospinal fluid and plasma — the two most extensively studied isoforms in Alzheimer's disease pathology research — using electrochemiluminescence (ECL) technology with pre-configured V-PLEX and S-PLEX platforms.

The Aβ42/Aβ40 ratio is a core cerebrospinal fluid biomarker in the AT(N) research framework for Alzheimer's disease, reflecting cerebral amyloid deposition with high concordance to amyloid PET imaging. Plasma Aβ measurements present unique analytical challenges due to their low abundance and matrix interference — our MSD platform's electrochemiluminescence detection overcomes these limitations, delivering the precision required for robust ratio determination in research applications.

Inquire About Aβ40/Aβ42 Testing Learn More

Aβ40 and Aβ42 in Alzheimer's Disease Research

Amyloid-beta (Aβ) peptides are proteolytic fragments of the amyloid precursor protein (APP) generated through sequential cleavage by β- and γ-secretases. Among the various Aβ isoforms, the 40-amino-acid (Aβ40) and 42-amino-acid (Aβ42) species are the most abundant and the most extensively studied in the context of Alzheimer's disease pathology. Aβ42 is more hydrophobic and aggregation-prone than Aβ40, serving as the primary component of amyloid plaques — the defining neuropathological hallmark of Alzheimer's disease.

 Why the Aβ42/Aβ40 Ratio Matters
Superior to Aβ42 alone: The Aβ42/Aβ40 ratio normalizes for inter-individual variation in total Aβ production and pre-analytical factors, providing better concordance with amyloid PET than Aβ42 concentration alone in published cohort studies.
AT(N) framework core biomarker: The Aβ42/Aβ40 ratio (or Aβ42 alone) is the established "A" (amyloid) component of the AT(N) research classification system for Alzheimer's disease.
Early changes in disease cascade: CSF Aβ42 and the Aβ42/Aβ40 ratio decrease early in the Alzheimer's continuum — detectable years before cognitive symptoms in autosomal dominant AD mutation carriers.
Plasma translation: Advances in immunoassay sensitivity have enabled reliable plasma Aβ42/Aβ40 measurement, opening the door to scalable, non-invasive amyloid pathology assessment in research settings.
Therapeutic target engagement: Aβ40 and Aβ42 measurements support pharmacodynamic assessment of amyloid-targeting investigational therapies, including secretase modulators and anti-amyloid antibodies.

Research Applications

Cohort enrichment for amyloid positivity — use plasma or CSF Aβ42/Aβ40 ratio to identify research participants likely to have cerebral amyloid deposition, reducing reliance on PET imaging for observational and interventional study enrollment.
Longitudinal biomarker tracking — monitor Aβ40 and Aβ42 trajectories over time to assess pharmacodynamic effects of amyloid-modulating investigational therapies.
Population-based aging research — scalable blood-based amyloid assessment for large epidemiological cohorts and longitudinal aging studies.
Translational research — support preclinical and clinical therapeutic development with analytically robust Aβ measurements across biological matrices.
Multi-marker panels — combine Aβ40/Aβ42 with p-Tau isoforms, NfL, and GFAP for comprehensive AT(N) biomarker profiling in a single workflow.

Aβ40/Aβ42 Assay Performance

Representative performance metrics for MSD-based Aβ40 and Aβ42 quantification in cerebrospinal fluid and plasma research applications.

0.90 AUC

CSF Aβ42/Aβ40 vs. Amyloid PET
(Published cohort data)

~0.75 AUC

Plasma Aβ42/Aβ40 vs. Amyloid PET
(Representative published value)

<5% CV

Intra-Plate Precision
Across QC levels

Note: Values are illustrative and drawn from published literature for informational purposes. Individual study results vary by cohort, matrix, and pre-analytical protocols. These metrics do not constitute performance claims for clinical diagnostic use.

Standard Curve & Linearity

8-point calibration curve with R² ≥ 0.99 for both Aβ40 and Aβ42. Synthetic peptide calibrators traceable to reference preparations. Dilution linearity verified at 1:2, 1:4, and 1:8 in human CSF and plasma matrices.

Precision & Reproducibility

Intra-plate CV <5% for both Aβ40 and Aβ42 across low, medium, and high QC samples. Inter-plate CV <10%. Three independent QC levels run in duplicate on each plate. Lot-to-lot bridging data available.

Ratio Reproducibility

The Aβ42/Aβ40 ratio demonstrates superior longitudinal reproducibility compared to individual analyte concentrations, with <3% CV for ratio measurements across replicates. This is particularly valuable for cohort enrichment and longitudinal monitoring studies.

How MSD Quantifies Aβ40 and Aβ42

Why precise ratio determination demands robust immunoassay technology — and how electrochemiluminescence delivers.

Analytical Requirements for Amyloid-Beta Measurement

Plasma Aβ peptides circulate at 10–100 pg/mL — levels that challenge conventional ELISA platforms. More importantly, Aβ42 is prone to aggregation and non-specific binding to collection tubes and assay surfaces, introducing pre-analytical variability that can distort the Aβ42/Aβ40 ratio. Matrix effects from plasma proteins further complicate accurate quantification. The MSD platform addresses each of these challenges through its unique electrochemiluminescence detection architecture.

ECL Detection Advantages for Aβ Quantification

1. Carbon Electrode Surface

MSD's high-capacity carbon electrode provides ~10× greater binding surface than polystyrene, minimizing non-specific binding of aggregation-prone Aβ42 and ensuring consistent capture efficiency across the concentration range.

2. SULFO-TAG ECL Detection

Non-enzymatic SULFO-TAG labels emit light only upon electrical stimulation at the electrode surface. No enzymatic amplification means no substrate depletion, no edge effects, and zero background from sample matrix autofluorescence — critical for low-abundance plasma Aβ detection.

3. Simultaneous Duplex Readout

Aβ40 and Aβ42 are measured in the same well using distinct capture antibodies spotted on spatially separated electrode areas. The ratio is computed from within-well signals, eliminating well-to-well variability as a source of ratio imprecision.

4. Wide Dynamic Range

ECL's 4–5 log dynamic range accommodates both CSF (ng/mL range) and plasma (pg/mL range) Aβ measurements without dilution adjustment, enabling cross-matrix comparison within a single assay platform.

Aβ40/Aβ42 Assay Specifications

TechnologyMSD V-PLEX / S-PLEX

AnalytesAβ1–40, Aβ1–42

LOD (CSF)~1–5 pg/mL

LLOQ (Plasma)~5–10 pg/mL

Dynamic Range1–10,000 pg/mL (4+ logs)

Sample Volume25 µL per well

Recommended MatrixCSF, EDTA Plasma

Acceptable MatricesSerum (consultation recommended)

Intra-Assay CV<5%

Inter-Assay CV<10%

Plate Format96-well MULTI-ARRAY

Multiplex Option+ Tau, p-Tau, NfL, GFAP

AD Biomarker Comparison: Amyloid vs. Other Targets

Relative concordance with amyloid PET in published research cohorts

CSF Aβ42/Aβ40 5/5

CSF p-Tau181 4.5/5

Plasma p-Tau217 4.4/5

Plasma Aβ42/Aβ40 3.8/5

Plasma GFAP 3.2/5

Plasma NfL 2/5*

* NfL is a non-specific marker of axonal injury, not directly reflective of amyloid pathology. Scores reflect amyloid PET concordance based on published head-to-head cohort studies. For research reference only.

Aβ40/Aβ42 Assay Service Details

Service package, sample requirements, and deliverables.

Service Package

Item	Full Service	Kit Only
Sample Processing	Included	— Self-run
Standard Curve	8-point, each plate	Reagents provided
QC Samples	3 levels, duplicate	— User-prepared
Ratio Calculation	Aβ42/Aβ40 ratio reported	— Self-analysis
Data Analysis	Full report	— Self-analysis
Raw Data	Included	— Instrument-dependent

For Research Use Only. Not for diagnostic procedures.

Sample Submission Requirements

Preferred MatrixCSF (for optimal Aβ42/Aβ40 ratio performance), EDTA Plasma

AcceptableSerum (consultation required; clotting process may influence Aβ levels)

Typical Sample Volume50–200 µL per aliquot. Minimum 25 µL per well. We'll advise exact requirements based on your study design.

Collection (CSF)Polypropylene collection tube → centrifuge at 2,000×g/10 min/4°C → aliquot into polypropylene cryovials → −80°C

Collection (Plasma)EDTA tube → 1,500×g/10 min/4°C → aliquot → −80°C

Critical NoteUse polypropylene (NOT polystyrene) tubes and plates for all Aβ sample handling — Aβ42 adsorbs to polystyrene surfaces, potentially biasing ratio measurements.

ShippingDry ice, overnight courier

DocumentationSample manifest form (provided)

How to Get Started

Consult

Tell us about your study — matrix type, cohort size, longitudinal design. We'll recommend the optimal assay configuration and pre-analytical protocol.

Ship

Send your samples on dry ice following our collection guidelines. We provide detailed tube-type and handling recommendations to preserve Aβ integrity.

Receive Data

Receive your complete data package — quantitative report with Aβ42/Aβ40 ratios, QC metrics, and methods documentation formatted for Aβ research publications.

First time measuring Aβ? Ask about our pre-analytical consultation — we'll help you select appropriate collection tubes and develop an aliquot strategy to minimize pre-analytical variability in ratio measurements.

Aβ40/Aβ42 Detection: MSD vs Other Platforms

Platform comparison for research applications.

Feature	MSD V-PLEX	Simoa (Quanterix)	Conventional ELISA	LC-MS/MS
Sensitivity (LOD)	1–5 pg/mL	fg/mL–pg/mL	~10–50 pg/mL	~5–10 pg/mL
Dynamic Range	4–5 logs	4 logs	2–3 logs	3–4 logs
Simultaneous Aβ40+Aβ42	Yes — within-well duplex	Requires separate wells	Separate kits required	Yes — multiplexed MS
Ratio Precision	Excellent (within-well)	Good (cross-well)	Moderate	Very good
Sample Volume	25 µL	~100 µL	100 µL	250–500 µL
Multiplex Capability	Up to 10-plex	Up to 4-plex	Single-plex only	Targeted panels
Throughput	96-well / 70 sec read	~60 samples/hr	96-well batch	Low (~20/day)
Best Research Fit	Cohort studies, AD trials, multiplex neuro panels	Ultra-low plasma Aβ, single-marker studies	Small pilot studies, CSF only	Isoform-specific, reference method

For a detailed head-to-head analysis covering all neuro biomarkers, see our Luminex vs MSD vs Simoa: A CRO Guide to Multiplex Cytokine Studies.

What You Receive

Quantitative report — Aβ40, Aβ42 concentrations + Aβ42/Aβ40 ratio, QC metrics, standard curve parameters (Excel + PDF)
Raw ECL data — per-well signal values, plate maps, curve plots — analysis-ready formats
Methods summary — formatted for direct use in Aβ-focused research manuscript Methods sections
QC documentation — intra/inter-plate CV, LOD/LLOQ, dilution linearity, ratio reproducibility
Sample tracking log — receipt to analysis chain-of-custody
Consultation — post-delivery call covering Aβ ratio interpretation and pre-analytical considerations

Why Our Clients Choose Us

Within-well Aβ40/Aβ42 duplex — both peptides measured simultaneously in the same well on spatially separated electrode spots, delivering superior ratio precision by eliminating well-to-well variation
Low Aβ42 adsorption surface — MSD carbon electrode minimizes non-specific binding compared to polystyrene ELISA plates, reducing a key source of pre-analytical bias in Aβ42 measurement
Polypropylene-optimized workflow — collection tube, aliquot, and plate recommendations specifically validated for amyloid-beta peptide stability throughout the entire sample lifecycle
Background-free ECL detection — electrical excitation eliminates plasma autofluorescence interference, enabling cleaner low-abundance Aβ quantification than optical immunoassays
AT(N)-ready extensibility — combine Aβ40/Aβ42 with p-Tau isoforms, NfL, and GFAP via U-PLEX for comprehensive AD biomarker profiling from a single 25 µL sample

Supporting Publications

Published research supporting Aβ40/Aβ42 and the Aβ42/Aβ40 ratio as biomarkers for Alzheimer's pathology.

Olsson B, Lautner R, Andreasson U, et al. (2016) Alzheimer's & Dementia. 12(7):719–732. "CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis." DOI: 10.1016/j.jalz.2016.01.005 · PMID: 27179972

Janelidze S, Stomrud E, Palmqvist S, et al. (2016) Scientific Reports. 6:26801. "Plasma β-amyloid in Alzheimer's disease and vascular disease." DOI: 10.1038/srep26801 · PMID: 27241045

Schindler SE, Bollinger JG, Ovod V, et al. (2019) Neurology. 93(17):e1647–e1659. "High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis." DOI: 10.1212/WNL.0000000000008081 · PMID: 31371569

Palmqvist S, Janelidze S, Stomrud E, et al. (2019) JAMA Neurology. 76(9):1060–1069. "Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β-Amyloid Status." DOI: 10.1001/jamaneurol.2019.1632 · PMID: 31233127

Ovod V, Ramsey KN, Mawuenyega KG, et al. (2017) Alzheimer's & Dementia. 13(8):841–849. "Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis." DOI: 10.1016/j.jalz.2017.06.2266 · PMID: 28734653

Nakamura A, Kaneko N, Villemagne VL, et al. (2018) Nature. 554(7691):249–254. "High performance plasma amyloid-β biomarkers for Alzheimer's disease." DOI: 10.1038/nature25456 · PMID: 29420472

References provided for informational and scientific context. For Research Use Only.

Aβ40/Aβ42 Assay FAQ

Is this Aβ40/Aβ42 assay validated for clinical diagnostic use?

No. This Aβ40/Aβ42 assay is validated for research use only (RUO). It is suitable for preclinical studies, cohort research, biomarker discovery, and therapeutic development applications. It is not validated for clinical diagnostic procedures, patient management decisions, or as a standalone screening tool in a clinical setting. All data is reported with the explicit disclaimer that it should not be used as the sole basis for clinical decision-making.

Why is the Aβ42/Aβ40 ratio important — can't I just measure Aβ42 alone?

The Aβ42/Aβ40 ratio consistently outperforms Aβ42 concentration alone in published research studies for identifying individuals with cerebral amyloid deposition. The ratio normalizes for inter-individual differences in total Aβ production and pre-analytical factors (e.g., sample dilution, collection tube binding). In the AT(N) research framework, the Aβ42/Aβ40 ratio is the recommended amyloid biomarker metric. Our MSD platform measures both analytes simultaneously in the same well, providing the most robust ratio determination possible.

Which sample matrix gives the best results — CSF or plasma?

CSF provides the strongest signal and highest concordance with amyloid PET, with the Aβ42/Aβ40 ratio achieving AUC values of ~0.90 in published cohort studies. Plasma measurements have improved significantly with newer assay platforms and can achieve AUC values of ~0.75–0.85. The choice depends on your research design: CSF for maximum accuracy in smaller studies; plasma for scalable, non-invasive assessment in large cohorts and longitudinal designs. We support both matrices and can advise on the optimal approach for your research objectives.

What tube types and collection protocols do you recommend?

Aβ42 is prone to non-specific adsorption to polystyrene surfaces — always use polypropylene tubes and plates for collection, aliquot, and storage. For CSF: collect directly into a polypropylene tube, centrifuge at 2,000×g/10 min/4°C, aliquot into polypropylene cryovials, freeze at −80°C. For plasma: collect in EDTA tubes (preferred over heparin or citrate), centrifuge at 1,500×g/10 min/4°C, transfer to polypropylene cryovials, freeze at −80°C. Avoid repeated freeze-thaw cycles. Contact us for a detailed pre-analytical guide.

Can Aβ40/Aβ42 be multiplexed with Tau or p-Tau assays?

Yes. Through MSD's U-PLEX custom platform, Aβ40 and Aβ42 can be combined with total Tau, p-Tau181, p-Tau217, p-Tau231, NfL, and GFAP in a single well for comprehensive AT(N) profiling. The within-well duplex measurement of Aβ40 and Aβ42 is preserved in multiplex configurations. Contact us to design a custom panel tailored to your research objectives — we'll help balance sensitivity requirements with multiplexing needs.

How should I prepare samples for shipping?

Collect CSF or blood per the recommended protocol → centrifuge at specified conditions → transfer to polypropylene cryovials (critical for Aβ) → freeze immediately at −80°C → ship on dry ice via overnight courier. Include a completed sample manifest form. Avoid repeated freeze-thaw cycles. Contact us for a detailed sample collection and shipping guide, including tube-type recommendations and aliquot volume guidance.

Demo Assay Report

See How Your Assay Results Are Reported

Request a representative report to review how assay methods, standard curves, quality-control metrics, and quantitative results are presented.

Assay methods
Standard curves
QC metrics
Quantitative results

Representative formatContents vary by assay and project

RESULTS OVERVIEW

CREATIVE PROTEOMICSREPRESENTATIVE REPORT

PROTEIN & BIOMARKER ANALYSIS

Assay Report

Methods · Standard Curves · QC · Results

ASSAY SERVICESFOR RESEARCH USE ONLY

REPRESENTATIVE REPORT FORMAT Assay methods, QC metrics, and quantitative results

Demo report

Inquiry Basket

Inquiry